Recurrence and metastasis are the main causes of treatment failure of NPC. Preliminary
clinical studies have found that the overall response rate of PD-1 inhibitors in treating ≥2
line R/M NPC is about 25%.
Recent studies have shown that G-CSF can significantly increase the proportion of effector
cells dominated by CD4+ T cells, improve the diversity of peripheral blood TCR, and regulate
the immune status of patients. Therefore, we suspect that G-CSF may have a synergistic effect
on PD-1 inhibitor, thus enhance the efficacy of PD-1 inhibitor monotherapy.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.